

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Moussaoui-Mrabet et al.

Examiner: **A. Falk**

Art Unit: **1632**

Application No.: **10/088,138**

Filed: **November 25, 2002**

Title: **NOVEL ANIMAL MODEL OF
ALZHEIMER DISEASE WITH AMYLOID
PLAQUES AND MITOCHONDRIAL
DYSFUNCTIONS**

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98


Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☐ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

- ☒ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



Ann Marie Szczepaniak, Reg. No. 52,267
Agent for Applicant

sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4757
Telefax (908) 231-2626
sanofi-aventis Docket No. ST99040 US PCT

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **2** of **4****Complete if Known**

Application Number	10/088,138
Filing Date	11-25-2002
First Named Inventor	MOUSSAOUI-MRABET
Group Art Unit	1632
Examiner Name	FALK, Anne Marie
Attorney Docket Number	ST99040 - US - PCT

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BORCHELT et al., Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins, <i>Neuron</i> , Vol. 19, Oct. 1997, pp. 939-945	
		CAMPION, Dominique et al., A novel presenilin 1 mutation resulting in familial Alzheimer's disease with an onset age of 29 years, <i>NeuroReport</i> , (1996), Vol. 7, pp. 1582 - 1584	
		CHEN et al., Neurodegenerative Alzheimer-like pathology in PDAPP 717V-F transgenic mice, <i>Progr. Br. Res.</i> Vol. 117, 1998, pp. 327-334	
		CHUI et al., Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation, <i>Nature Medicine</i> , Vol. 5, No. 5, May 1999, pp. 580-584	
		CZECH et al., Characterization of Human Presenilin 1 Transgenic Rats: Increased Sensitivity To Apoptosis in Primary Neuronal Cultures, <i>Neuroscience</i> , Vol. 87, No. 2, pp. 325-336, 1998	
		CZECH et al., Proteolytic processing of mutated human amyloid precursor protein in transgenic mice, <i>Mol. Br. Res.</i> Vol. 47, 1997, pp. 108-116	
		GUO et al., Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid Beta-peptide, <i>Neuroreport</i> , Vol. 8, No. 1, Dec. 1996, pp. 379-383	
		GUO et al., Alzheimer's Presenilin Mutation Sensitizes Neural Cells to Apoptosis Induced by Trophic Factor Withdrawal and Amyloid Beta-Peptide: Involvement of Calcium and Oxygen Radicals, <i>J. Of Neuroscience</i> , Vol. 17, No. 11, June, 1997, pp. 4212-4222	
		HOLCOMB et al., Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes, <i>Nature Medicine</i> , Vol. 4, No. 1, Jan. 1998, pp. 97-100	
		HSIAO et al., Correlative Memory Deficits, ABeta Elevation, and Amyloid Plaques in Transgenic Mice, <i>Science</i> , Vol. 274, 1996, pp. 99-102	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete the form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **3** of **4****Complete if Known**

Application Number	10/088,138
Filing Date	11-25-2002
First Named Inventor	MOUSSAOUI-MRABET
Group Art Unit	1632
Examiner Name	FALK, Anne Marie
Attorney Docket Number	ST99040 - US - PCT

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
		IRIZARRY et al., A Beta Deposition is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP Transgenic Mouse), J. of Neuroscience, Sept. 15, 1997, Vol. 17, No. 18, pp. 7053-7059	
		IRIZARRY et al., APPsw Transgenic Mice Develop Age-related Abeta Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1, J. of Neuropathology and Experimental Neurology, Vol. 56, No. 8, Sept. 1997, pp. 965-973	
		JOHNSON-WOOD et al., Amyloid precursor protein processing and A Beta42 deposition in a transgenic mouse model of Alzheimer disease, PNAS, Vol. 94, Feb. 1997, pp. 1550-1555	
		LEUTNER et al., Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations, Neuroscience Letters, Vol. 292, 2000, pp. 87-90	
		MASLIAH et al., Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F Beta-Amyloid Precursor Protein and Alzheimer's Disease, J. of Neuroscience, Sept. 15, 1998, Vol. 18, No. 18, pp. 5795-5811	
		MOECHARS et al., Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain, J. of Biol. Chem., Vol. 274, No. 10, March 5, 1999, pp.6483-6492	
		MOECHARS et al., Premature Death in Transgenic Mice That Overexpress A Mutant Amyloid Precursor Protein is Preceded By Severe Neurodegeneration And Apoptosis, Neuroscience, Vol. 91, No. 3, 1999, pp. 819-830	
		MOECHARS et al., Transgenic mice expressing an alpha-secretion mutant of the amyloid precursor protein in the brain develop a progressive CNS disorder, Behavioural Brain Res., Vol. 95, 1999, pp. 55-64	
		PAPPOLLA et al., Evidence of Oxidative Stress and in Vivo Neurotoxicity of Beta-Amyloid in a Transgenic Mouse Model of Alzheimer's Disease, Am. J. of Pathology, Vol. 152, No. 4, April 1998, pp. 871-877	
		PRICE et al., Mutant Genes in Familial Alzheimer's Disease And Transgenic Models, Annu. Rev. Neurosci. 1998, Vol. 21, pp. 479-505	

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete the form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND PAGES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B-PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known

Application Number	10/088,138
Filing Date	11-25-2002
First Named Inventor	MOUSSAOUI-MRABET
Group Art Unit	1632
Examiner Name	FALK, Anne Marie
Attorney Docket Number	ST99040 - US - PCT

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ROCKENSTEIN et al., Early Formations of Mature Amyloid-Beta Protein Deposits in a Mutant APP Transgenic Model Depends on Levels of AlphaBeta1-42, J. of Neuroscience Research, Vol. 66, 2001, pp. 573-582	
		SMITH et al., Amyloid Beta Deposition in Alzheimer Transgenic Mice is Associated With Oxidative Stress, J. of Neurochemistry, Vol. 70, No. 5, 1998 pp. 2212-2215	
		STURCHLER-PIERRAT et al., Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology, PNAS, Vol. 94, Nov. 1997, pp. 13287-13292	
		TAKEUCHI et al., Age-Related Amyloid Beta Deposition in Transgenic Mice Overexpressing Both Alzheimer Mutant Presenilin 1 and Amyloid Beta Precursor Protein Swedish Mutant is Not Associated with Global Neuronal Loss, Am. J. of Pathology, Vol. 157, No. 1, July 1, 2000, pp. 331-339	

Examiner
SignatureDate
Considered¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.